Morning Summary - Jul 14 2026

研报英文原文证据摘录

Morning Summary - Jul 14 2026

ially registration-enabling studies in 2L+ NSCLC, 1L PDAC (Ph 3), and

RASm NSCLC (Ph 3) during 1H27, 2027, and 2H27/1H28, respectively. We view yesterday's update as incremental, relative to the earlier, April 2026 data

disclosure and believe most investors view presentation of mature U.S. Phase 1b safety/efficacy dose-expansion data at RP2D in "dozens" of patients per

histology as the next key de-risking data disclosure. Next up, we expect ERAS to present preliminary dose-escalation data from the Phase 1 BOREALIS-1

study of ERAS-4001 (pan-KRASi) in 2H 2026.

GLOBAL BIOPHARMACEUTICALS

Global Biopharma: Previewing 2Q26 Large Cap Pharma Earnings; Guggenheim Investor Webinar Tuesday, July 14 at 2pm ET

Vamil Divan, M.D.

212 823 6543, vamil.divan@guggenheimpartners.com

Seamus Fernandez

617 859 4637, seamus.fernandez@guggenheimpartners.com

CLICK HERE TO ACCESS THIS REPORT

Published on July 13, 2026

Key Message: Ahead of our investor webinar previewing 2Q 2026 earnings for our large cap pharma coverage and discussing our favorite ideas for 2H

2026, we provide here a summary of our recently published earnings preview work. Links to each individual earnings preview note are also provided below.

Our webinar will be held tomorrow, July 14th at 2pm ET. Please register for the webinar HERE or contact us or your Guggenheim Sales Representative

to register.

TARSUS PHARMACEUTICALS, INC. Buy

TARS - CCO Aziz Mottiwala Departs for CEO Role; Xdemvy 2026

Guidance Reiterated TARS $59.31 Price$90.00TargetEddie Hickman, Ph.D.

212 518 9904, eddie.hickman@guggenheimpartners.com

Current Q Next Q Current FY Next FY

Yatin Suneja

212 518 9565, yatin.suneja@guggenheimpartners.com $168.0 $180.0 $688.4 $935.0